Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal amphotericin B for visceral leishmaniasis in Bangladesh
ACTRN12609001029280Phase 3Active, not recruiting
- Sponsor
- UNICEF
- Start
- Feb 2010
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of liposomal amphotericin b in visceral leishmaniasis (VL), sponsored by UNICEF. Primary endpoint: Efficacy of liposomal amphotericin B. Started Feb 2010; status: active, not recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on ACTRN12609001029280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609001029280.